Recent research have centered on the overlap of GLP-1|GIP|glucagon receptor stimulant therapies and dopaminergic signaling. While GLP agonists are increasingly employed for addressing type 2 diabetes, their emerging impacts on motivation circuits, specifically governed by dopaminergic networks, are receiving substantial interest. This report detail